TABLE 2.
Meropenem and nacubactam %T > ELF concentration values estimated in humans and in mice
| Drug and species | %T > ELF concentration of: |
AUC0–24 (μg·h/ml) | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 0.5 μg/ml | 1 μg/ml | 2 μg/ml | 4 μg/ml | 8 μg/ml | 16 μg/ml | 32 μg/ml | 64 μg/ml | ||
| Meropenem | |||||||||
| Human (2 g every 8 h, 1.5-h infusion) | 94.58 | 78.33 | 60.83 | 42.08 | 20.83 | 0.00 | 0.00 | 0.00 | 104 |
| Mousea | 92.50 | 81.25 | 61.25 | 40.00 | 21.25 | 5.83 | 0.00 | 0.00 | 121 |
| Mouseb | 88.75 | 75.83 | 55.00 | 33.75 | 18.83 | 0.00 | 0.00 | 0.00 | 94 |
| Nacubactam | |||||||||
| Human (2 g every 8 h, 1.5-h infusion) | 100.00 | 100.00 | 100.00 | 80.42 | 55.42 | 26.67 | 0.00 | 0.00 | 265 |
| Mousec | 100.00 | 100.00 | 88.75 | 72.08 | 53.33 | 16.67 | 0.00 | 0.00 | 220 |
| Moused | 100.00 | 99.58 | 86.25 | 73.75 | 55.00 | 19.58 | 0.00 | 0.00 | 240 |
a
Meropenem human-simulated regimen administered alone.
b
Meropenem human-simulated regimen coadministered with nacubactam human-simulated regimen.
c
Nacubactam human-simulated regimen administered alone.
d
Nacubactam human-simulated regimen coadministered with meropenem human-simulated regimen.